A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia.

Autor:	Piatek CI; Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA, caroline.piatek@med.usc.edu.; Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA, caroline.piatek@med.usc.edu., Bocian H; Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA., Algaze S; Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA.; Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA., Weitz IC; Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA.; Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA., O'Connell C; Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA.; Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA., Liebman HA; Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA.; Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA.
Jazyk:	angličtina
Zdroj:	Acta haematologica [Acta Haematol] 2020; Vol. 143 (3), pp. 244-249. Date of Electronic Publication: 2019 Oct 30.
DOI:	10.1159/000501538
Abstrakt:	The combination of rituximab, cyclophosphamide, and dexamethasone (RCD) is highly effective in the treatment of warm autoimmune hemolytic anemia (WAIHA) associated with chronic lymphocytic leukemia (CLL). We treated a cohort of patients with relapsed/refractory WAIHA, without CLL, with RCD. The primary objective was to evaluate the overall response (OR) of RCD therapy. Complete response (CR) was defined as a hemoglobin (Hgb) ≥12 g/dL. Partial response (PR) was defined as Hgb 10-11.9 g/dL or ≥2 g/dL increase in Hgb. Sustained response was defined as Hgb ≥10 g/dL with no treatment changes. A total of 16 patients with relapsed/refractory WAIHA received RCD (7 primary WAIHA, 9 secondary WAIHA) for a median of 4 cycles (range: 2-6). The median pretreatment Hgb was 10.0 g/dL (range: 4.3-12.2). The median best Hgb achieved was 12.5 g/dL (range: 10.6-15.1) with a median of 2 cycles until best Hgb response. The OR was 94% (11 CR, 4 PR). Two immunocompromised patients were admitted for infections during RCD treatment. There were no deaths during the treatment or follow-up period. Following a response to RCD, 4 patients received noncorticosteroid immune modulation therapy and 4 patients continued on corticosteroid therapy. Seven patients received no additional treatment. (© 2019 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu